Vativio 10 mg/400 mg FC tablets
PDF Leaflet Revision Date: 16 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various hematological malignancies including CML and Ph+ ALL.
Dosage (summary)
400 mg/day for chronic phase CML; 600 mg/day for accelerated phase or blast crisis; 800 mg/day for DFSP.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation due to potential fetal harm.
Key Drug Interactions
- CYP3A4 inducers (e.g., rifampicin)
- CYP3A4 inhibitors (e.g., ketoconazole)
- Warfarin
Contraindications
- Hypersensitivity to imatinib
- Pregnancy
- Lactation
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Headache
- Nausea
Counselling Points
- Take with food and a large glass of water
- Monitor for signs of liver dysfunction
- Report any rapid weight gain
Serious warnings
- Hepatitis B reactivation
- Severe fluid retention
- Hepatotoxicity
- Cardiac failure
Important Disclaimer
The Vativio 10 mg/400 mg FC tablets professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
